MESA LABORATORIES INC (MLAB) is the issuer of common stock that former officer Gary M. Owens has notified for potential sale under Rule 144. The notice covers up to 20,358 shares of common stock, with an indicated aggregate market value of $2,600,734.50 and shares outstanding of 5,595,869.
The shares to be sold were acquired through multiple restricted stock vesting events between June 2020 and June 2026 as compensation from the issuer. The notice also lists Owens’s prior sales over the past three months, executed through Fidelity Brokerage Services LLC acting as attorney-in-fact.
MESA LABORATORIES INC (MLAB) is the subject of a Rule 144 notice filed for the potential sale of its common stock by former officer Gary M. Owens. The notice covers up to 20,000 shares of common stock to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $2,450,059.20 and 5,595,869 shares of common stock outstanding as context. The shares were acquired through restricted stock vesting grants between 2018 and 2025. The form also notes a prior sale by Owens of 3,706 shares on June 16, 2026 for $375,295.50.
Mesa Laboratories director Mark Christopher Capone reported the vesting and exercise of 2,784 Restricted Stock Units into an equal number of shares of common stock on August 15, 2026. The derivative RSU position was reduced to zero in this transaction, and his directly held common stock position increased to 6,213 shares.
Mesa Laboratories director Jennifer Sadie Alltoft reported the vesting and settlement of 2,784 Restricted Stock Units (RSUs) into common stock of Mesa Laboratories Inc. Each RSU represented one share of common stock and vested on August 15, 2026. On that date, 2,784 RSUs were exercised and disposed of as derivatives, and 2,784 shares of common stock were acquired at a stated price of $0.00 per share. Following these transactions, Alltoft directly held 7,662 shares of common stock and had no remaining holdings in the reported RSU award. The filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.
For MESA LABORATORIES INC (MLAB), director Shiraz Shabanali Ladiwala reported the vesting and settlement of 3,810 Restricted Stock Units (RSUs) on August 15, 2026. The RSUs, each representing a contingent right to one share of common stock, were exercised at $0.00 per share, converting into 3,810 shares of common stock. Following this transaction, Ladiwala directly holds 12,333 shares of MLAB common stock.
Mesa Laboratories, Inc. (MLAB) director Shannon Hall reported the vesting and settlement of 2,784 Restricted Stock Units into an equal number of shares of common stock on August 15, 2026. The derivative RSU position was reduced to zero, and Hall now directly holds 6,973 shares of common stock.
Mesa Laboratories director R. Tony Tripeny reported the vesting and settlement of 2,784 Restricted Stock Units (RSUs) into 2,784 shares of common stock on August 15, 2026. The RSUs, each representing a contingent right to one common share, vested on that date, increasing his directly held common stock to 9,082 shares. The derivative RSU position was reduced to zero as a result of this exercise and conversion.
Mesa Laboratories director John James Sullivan reported the vesting and settlement of 2,784 Restricted Stock Units, each converting into one share of common stock at $0.00 per share, on August 15, 2026. This exercise eliminated the RSU balance and increased his directly held common stock to 20,618 shares. He is also reported as having 45,110 shares of common stock held indirectly by the “Sullivan Family Trust,” for which his spouse serves as trustee, and he disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Mesa Laboratories director John James Sullivan reported selling 7,093 shares of common stock of MLAB on 2026-08-13 at $112.80 per share in a private transaction to President and CEO Siddhartha Kadia. After this sale, Sullivan directly holds 17,834 shares and is also reported as having an indirect interest in 45,110 shares held by the Sullivan Family Trust, for which his spouse is trustee; he disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Mesa Laboratories (MLAB) President and CEO Siddhartha Kadia reported that the Anjou Parekh Lifetime Access Trust, for which his spouse serves as trustee, purchased 7,093 shares of Common Stock at $112.80 per share in a private transaction from Board Chair John Sullivan. The trust now holds 7,093 shares, reported as indirect ownership. Kadia disclaims beneficial ownership of the trust’s shares except to the extent of his pecuniary interest. The transaction was not reported as made under a Rule 10b5-1 trading plan.